Yean K Yong1, Esaki M Shankar, Ajantha Solomon, Tim Spelman, Christopher K Fairley, Julian H Elliott, Jennifer Hoy, Paul U Cameron, Adeeba Kamarulzaman, Sharon R Lewin. 1. aCentre of Excellence for Research in AIDS (CERiA) bTropical Infectious Diseases Research and Education Centre (TIDREC), Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia cThe Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital dCentre of Population Health, Burnet Institute eSchool of Public Health and Preventive Medicine, Monash University fMelbourne Sexual Health Centre, Alfred Hospital gCentral Clinical School, Monash University hDepartment of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia iInfectious Disease Unit, University Malaya Medical Centre, University of Malaya, Lembah Pantai, 50603 Kuala Lumpur, Malaysia jCentre for Biomedical Research, Burnet Institute, Melbourne, Australia.
Abstract
BACKGROUND: Chronic HIV infection leads to marked depletion of CD4 T cells in the gastrointestinal tract and increased microbial translocation measured by an increase in circulating lipopolysaccharide (LPS) levels. Here, we hypothesized that single-nucleotide polymorphisms (SNPs) in genes encoding the Toll-like receptor 4 (TLR4) and CD14, the principal receptors for LPS, were associated with CD4 T-cell recovery postantiretroviral therapy (ART). METHODS: Prospective study of predominantly white HIV-infected participants receiving suppressive ART for at least 12 months. We analysed the CD14 SNPs C-260T and the TLR4 SNPs A+896G, C+1196T. We also determined the levels of LPS and soluble CD14 in plasma samples collected pre-ART and post-ART initiation. CD4 T-cell recovery was assessed by linear mixed models. RESULTS: Following ART, individuals with a TT genotype compared with a CT or CC genotype for CD14 C-260T SNP showed higher levels of soluble CD14 (P = 0.008 and 0.003, respectively). The CC genotype for the CD14 C-260T SNP, compared with CT or TT, and the TLR4 SNP (AC/GT), compared with the homozygous genotype (AA/CC), were both independently associated with enhanced long-term CD4 T-cell recovery (>3 months; P < 0.001). CONCLUSION: Polymorphisms in CD14 and TLR4 are independently associated with long-term CD4 T-cell recovery in HIV-infected individuals post-ART.
BACKGROUND:Chronic HIV infection leads to marked depletion of CD4 T cells in the gastrointestinal tract and increased microbial translocation measured by an increase in circulating lipopolysaccharide (LPS) levels. Here, we hypothesized that single-nucleotide polymorphisms (SNPs) in genes encoding the Toll-like receptor 4 (TLR4) and CD14, the principal receptors for LPS, were associated with CD4 T-cell recovery postantiretroviral therapy (ART). METHODS: Prospective study of predominantly white HIV-infectedparticipants receiving suppressive ART for at least 12 months. We analysed the CD14 SNPs C-260T and the TLR4 SNPs A+896G, C+1196T. We also determined the levels of LPS and soluble CD14 in plasma samples collected pre-ART and post-ART initiation. CD4 T-cell recovery was assessed by linear mixed models. RESULTS: Following ART, individuals with a TT genotype compared with a CT or CC genotype for CD14 C-260T SNP showed higher levels of soluble CD14 (P = 0.008 and 0.003, respectively). The CC genotype for the CD14 C-260T SNP, compared with CT or TT, and the TLR4 SNP (AC/GT), compared with the homozygous genotype (AA/CC), were both independently associated with enhanced long-term CD4 T-cell recovery (>3 months; P < 0.001). CONCLUSION: Polymorphisms in CD14 and TLR4 are independently associated with long-term CD4 T-cell recovery in HIV-infected individuals post-ART.
Authors: R P Bucy; R D Hockett; C A Derdeyn; M S Saag; K Squires; M Sillers; R T Mitsuyasu; J M Kilby Journal: J Clin Invest Date: 1999-05-15 Impact factor: 14.808
Authors: N G Pakker; D W Notermans; R J de Boer; M T Roos; F de Wolf; A Hill; J M Leonard; S A Danner; F Miedema; P T Schellekens Journal: Nat Med Date: 1998-02 Impact factor: 53.440
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Peter W Hunt; Steven G Deeks; Benigno Rodriguez; Hernan Valdez; Starley B Shade; Donald I Abrams; Mari M Kitahata; Melissa Krone; Torsten B Neilands; Richard J Brand; Michael M Lederman; Jeffrey N Martin Journal: AIDS Date: 2003-09-05 Impact factor: 4.177
Authors: D C Douek; R D McFarland; P H Keiser; E A Gage; J M Massey; B F Haynes; M A Polis; A T Haase; M B Feinberg; J L Sullivan; B D Jamieson; J A Zack; L J Picker; R A Koup Journal: Nature Date: 1998-12-17 Impact factor: 49.962
Authors: Babafemi Taiwo; Peter W Hunt; Rajesh T Gandhi; Andrew Ellingson; Matthew McKenna; Jeffrey M Jacobson; Barbara Gripshover; Ronald J Bosch Journal: J Acquir Immune Defic Syndr Date: 2013-05-01 Impact factor: 3.731
Authors: Gottfried Rudofsky; Peter Reismann; Steffen Witte; Per M Humpert; Berend Isermann; Triantafyllos Chavakis; Jörg Tafel; Valery V Nosikov; Andreas Hamann; Peter Nawroth; Angelika Bierhaus Journal: Diabetes Care Date: 2004-01 Impact factor: 19.112
Authors: Brian K Kigozi; Samwel Sumba; Peter Mudyope; Betty Namuddu; Joan Kalyango; Charles Karamagi; Mathew Odere; Elly Katabira; Peter Mugyenyi; Francis Ssali Journal: AIDS Res Ther Date: 2009-07-24 Impact factor: 2.250
Authors: Yean K Yong; Esaki M Shankar; Clare L V Westhorpe; Anna Maisa; Tim Spelman; Adeeba Kamarulzaman; Suzanne M Crowe; Sharon R Lewin Journal: Medicine (Baltimore) Date: 2016-08 Impact factor: 1.889
Authors: Tongai Gibson Maponga; Monique I Andersson; Christoffel J van Rensburg; Joop E Arends; Jantjie Taljaard; Wolfgang Preiser; Richard H Glashoff Journal: BMC Infect Dis Date: 2018-05-08 Impact factor: 3.090
Authors: Salvador Resino; María Ángeles Jiménez-Sousa; Julià Blanco; Yolanda M Pacheco; Jorge Del Romero; Joaquim Peraire; Ana Virseda-Berdices; María José Muñoz-Gómez; Carlos Galera-Peñaranda; Lucio Jesus García-Fraile; José M Benito; Norma Rallón Journal: Front Pharmacol Date: 2022-01-18 Impact factor: 5.810